1. Phacell Bio IR Event: What Was Discussed?

The core of this IR event was ‘enhancing investor understanding and increasing corporate value’. The company explained its current management status and future business plans, and held a Q&A session with investors. Particular attention was focused on the performance after the merger with SH Pharm and AL Biotech, and the progress of anticancer immunotherapy development.

2. Q1 2025 Earnings Analysis: Light and Shadow

The Q1 2025 earnings showed both positive and negative aspects, with increased sales through mergers and continued operating losses due to anticancer immunotherapy development. While the approval of Boxleukin-15 and the sales contract with Yuhan Corp. are positive signals, the burden of R&D expenses still remains.

3. The Future of Phacell Bio in the High-Interest Rate Era

The current high-interest rate trend is a burden on the bio sector, which is a growth stock. Phacell Bio is also unable to avoid the impact of this macroeconomic environment. However, depending on the future business plans presented at the IR and the results of anticancer immunotherapy development, there is room for improvement in investor sentiment.

4. Action Plan for Investors

Short-term investors should carefully analyze the IR content and market reactions, while long-term investors should focus on the company’s technological capabilities and growth potential. Continuous monitoring of the progress of anticancer immunotherapy development is particularly important. Investment decisions should be made carefully after collecting and analyzing additional information.